Executive Committee

  • Riccardo Palmisano - MolMed

    President 
      

    Riccardo Palmisano, CEO at MolMed, is graduated in Medicine at Parma University. His career in the Italian pharmaceutical industry started in 1986 at Farmitalia Carlo Erba (1986), he then moved on to Gruppo Menarini (1988) where he contributed to the development and internationalisation of the first Italian pharmaceutical Group, becoming Director of the Pharmaceutical Division Italy in 1993 and General Manager at Lusofarmaco in 1995. His career in multinational companies started in 2000: he set up the Italian branch of Shire Pharmaceutical (2000), then he was appointed Vice President Commercial Retail Market in GlaxoSmithKline Verona (2003) and, lastly, Vice President & General Manager Italy at Genzyme (2005), a U.S. biotech company specialized in research and development of orphan drugs for rare diseases. After the acquisition of Genzyme by Sanofi he was appointed Director of Business Strategy and Development at Sanofi Italia (2012-2013). Between 2014 and 2015, before moving in MolMed, Palmisano was Genzyme not operating Chairman, President of Siena Biotech, as well as member of the Steering Committee of Rare Partners and consultant to some innovative startups in the life sciences area.   In 2008, he joined Assobiotec, becoming Vice President, responsible for biotech pharma and health, in 2010. In 2016, was appointed President of Assobiotec


  • francesco di marco

    FRANCESCO DI MARCO – Amgen

    Vice President 

    Francesco Di Marco is the CEO at Amgen S.r.l., the Italian affiliate of the Amgen Inc. Group, the world leading biotech. Francesco Di Marco has been directing the Italian affiliate since June 2011, after various International experiences within Amgen as Global Commercial lead Osteoporosis at Amgen’s headquarters in California, business Unit Oncology in Germany, International brand director filgrastin franchise and Business Unit Oncology Switzerland. He joined Amgen after a period at Eli Lilly. He holds a degree in Molecular biology from the University of Zurich and a PhD from the University of Lausanne obtained while working at Genentech in San Francisco and at the Swiss Institute for Experimental Cancer Research in Lausanne (ISREC). He is a Swiss and Italian citizen and, besides Italian, he speaks fluently English, German and French.

  • CARLO ROSA – DiaSorin

    Vice President

    Carlo Rosa, Chief Executive Officer of DiaSorin, graduated in 1990 in Chemistry from the University of Torino summa cum laude. In 1990, he moved to New York to work at the Public Health Research Institute on a project aimed at the development of a new innovative product for diagnosing Hepatitis CV infections. In 1992 he joined Incstar Corporation, (MN) USA, an American Public Company, and worked in the R&D department to lead a project in joint venture with Akzo Nobel. Then he held different positions both in the R&D and the Strategic Marketing departments until he took the role of Director of the Infectious Disease Business Unit. In 1998, he moved back to Italy to assume the role of Director of European S&M for DiaSorin Spa. In 2001, he led a management buy out  with four other managers and a group of financial investors to buy DiaSorin from the previous owner, American Standard Inc. As a result, he became the COO of the Company until 2006 when he was promoted CEO. In 2007 DiaSorin was listed on the Milan Stock exchange and become a Public Company. Since 2001, DiaSorin moved from less than 100 MM $ in revenues to over 500 MM $ employing more than 1700 people around the world. In 2014 Mr Rosa was nominated as Vice Chairman of Alisei, a consortium of private and public Italian entities intended to promote the development of Life Science in Italy. In 2016 he joins the Italian Institute of Technology Foundation as a Board Member.

  • Luca Benatti - EryDel

    Member

    Luca Benatti is CEO of EryDel S.p.A since 2012. He has over 25 year experience in Pharma and Biotech. He was Co-founder, CEO of Newron Pharmaceuticals, until May 2012. Under his guidance, Newron developed a pipeline of innovative therapies. During his tenure, Newron raised significant capital from international venture capital firms, and was listed at the Swiss Stock Exchange.  Also he  was instrumental in finalizing multimillion licensing deals with Merck Serono, Meiji Seika and Zambon, and in the acquisition of the UK biotech Company Hunter Fleming.  
    Benatti graduated and performed his post-doctoral training at Milano Genetics Institute. He is an independent Board member at Newron (Swiss Stock Exhange), Intercept Pharmaceuticals (Nasdaq), Chairman of the Scientific Advisory Board of Zambon, Vice President and member of the Board of Assobiotec and member of Jury of the European Biotechnica Award. He has authored several scientific publications and holds numerous patents.

  • boano

    LUIGI BOANO - Novartis

    Member

    Luigi Boano is the Oncology General Manager at Novartis Farma. In this position is the Head of the Management and Development of the overall performance of the business unit, the current portfolio and products in development, coordinating  the Marketing, Sales, Market access, Finance and Medical areas. He currently leads a staff of 300 employees, with a turnover of over 400 Million Euros. He gained experience of over 25 years in managerial positions in the Sales and Marketing Areas of Pharmaceutical Industry (Merk Sharp & Dohme, Sandoz, Novartis). Luigi Boano has a degree in Pharmacy and an MBA at the Bocconi University. He has attended several managerial courses at the most prestigious American universities: Marketing Excellence Program at Stanford University; One-X at Columbia University; Business Leadership Program, ED Finance Executive Forum V at Harvard University.

  • Giulia Gregori - Mater Biotech di Novamont

    Member 

    Giulia Gregori works in Novamont as Director of Strategic Planning & Corporate Communication. Novamont is a global market leader in bioplastics and in the development of biochemicals. Starting as a research centre in the 90s it became a profitable company, awarded and recognized at international level. Novamont is currently involved in several projects which entails conversion of petrolchemical sites in biorefineries in Italy with the aim to restore growth through bioeconomy. Giulia Gregori entered in Novamont in September 2000, after graduating in Pure Chemistry with a specialization in Bioinorganic from the University of Milan, in collaboration with Leiden University. Within Novamont she is responsible for Strategic R&D and Researcher Training Projects and Corporate Communication, and undertaking also external relationships with Public and Private Funding Institutions. She has been a member of several Associations and she is member of Biobased Industries Board, as well as member of the board of directors of Enne3 – Incubatore di impresa Novara-  and P.U.MA.S. (Polo di Innovazione Umbro Materiali Speciali e micro-nano Tecnologie).

  • Elena Sgaravatti - Demethra Biotech

    Member

    Elena Sgaravatti is CEO of Demethra Biotech Srl. After graduating with a Pharm. D. degree from Padova University, she developed more than twenty years of experience in the pharmaceutical sector, from business development to strategic marketing in multinational companies such as GSK. She was CEO at IRB Spa (Biotechnological Research Institute) until June 2016, a company she launched in 2009, when she joined as General Director, which was acquired by Croda Int. Plc, in 2012. She is the inventor of seven patents. She is coordinator of the Work Group on Food Biotechnologies in Assobiotec–Federchimica and a Member of its Presidential Committee. She is also a member of the academic course commission at the University of Medical Biotechnologies of Modena.